Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

May 2016 • Volume 15 • Number 5

Highlights of This Issue 765

REVIEWS

SMALL MOLECULE THERAPEUTICS

Table of Contents

Table of Contents

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The tetravalent FAP-DR5 bispecific antibody (RG7386) is rationally designed to exhibit bivalent binding to FAP and DR5. By simultaneous binding to both targets, the death receptor on tumor cells is being hyper–cross-linked, resulting in strictly target-dependent apoptosis induction of cancer cells. For details, see the article by Brünker, Wartha, and colleagues beginning on page 946.



Molecular Cancer Therapeutics

15 (5)

Mol Cancer Ther 2016;15:765-1152.